New AI model MFS-DLPSO-XGBoost achieves 94.1% accuracy in cardiovascular risk assessment, surpassing conventional methods. NIH funding and clinical pilots signal growing adoption amid regulatory debat...
New MFS-DLPSO-XGBoost AI model achieves 80% precision in cardiovascular risk assessment, endorsed by leading medical organizations as clinical trials show 41% reduction in missed diagnoses. A novel AI...
FDA-cleared AI tools now decode triple-negative breast cancer biomarkers in imaging scans, enabling earlier diagnosis and personalized therapies while raising ethical questions about algorithmic trans...
